823 related articles for article (PubMed ID: 17584117)
21. Glucocorticoid receptor is involved in the neuroprotective effect of ginsenoside Rg1 against inflammation-induced dopaminergic neuronal degeneration in substantia nigra.
Sun XC; Ren XF; Chen L; Gao XQ; Xie JX; Chen WF
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):94-103. PubMed ID: 26455404
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
23. Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease.
Jiang J; Kim JJ; Kim DY; Kim MK; Oh NH; Koppula S; Park PJ; Choi DK; Shin YK; Kim IH; Kang TB; Lee KH
J Ethnopharmacol; 2012 Dec; 144(3):506-13. PubMed ID: 23085397
[TBL] [Abstract][Full Text] [Related]
24. Vanillin Protects Dopaminergic Neurons against Inflammation-Mediated Cell Death by Inhibiting ERK1/2, P38 and the NF-κB Signaling Pathway.
Yan X; Liu DF; Zhang XY; Liu D; Xu SY; Chen GX; Huang BX; Ren WZ; Wang W; Fu SP; Liu JX
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208679
[TBL] [Abstract][Full Text] [Related]
25. Rubusoside mitigates neuroinflammation and cellular apoptosis in Parkinson's disease, and alters gut microbiota and metabolite composition.
Meng T; Zhang Y; Huang J; Pandey V; Fu S; Ma S
Phytomedicine; 2024 Feb; 124():155309. PubMed ID: 38237261
[TBL] [Abstract][Full Text] [Related]
26. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.
Çınar E; Tel BC; Şahin G
Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436
[TBL] [Abstract][Full Text] [Related]
27. Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Park JE; Leem YH; Park JS; Kim DY; Kang JL; Kim HS
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457238
[TBL] [Abstract][Full Text] [Related]
28. Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications.
Angelopoulou E; Paudel YN; Shaikh MF; Piperi C
Pharmacol Res; 2020 Aug; 158():104930. PubMed ID: 32445958
[TBL] [Abstract][Full Text] [Related]
29. Galectin-1 attenuates neurodegeneration in Parkinson's disease model by modulating microglial MAPK/IκB/NFκB axis through its carbohydrate-recognition domain.
Li Y; Chen N; Wu C; Lu Y; Gao G; Duan C; Yang H; Lu L
Brain Behav Immun; 2020 Jan; 83():214-225. PubMed ID: 31669519
[TBL] [Abstract][Full Text] [Related]
30. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.
García C; Gómez-Cañas M; Burgaz S; Palomares B; Gómez-Gálvez Y; Palomo-Garo C; Campo S; Ferrer-Hernández J; Pavicic C; Navarrete C; Luz Bellido M; García-Arencibia M; Ruth Pazos M; Muñoz E; Fernández-Ruiz J
J Neuroinflammation; 2018 Jan; 15(1):19. PubMed ID: 29338785
[TBL] [Abstract][Full Text] [Related]
31. Modulation of Inflammatory Mediators and Microglial Activation Through Physical Exercise in Alzheimer's and Parkinson's Diseases.
de Almeida EJR; Ibrahim HJ; Chitolina Schetinger MR; de Andrade CM; Cardoso AM
Neurochem Res; 2022 Nov; 47(11):3221-3240. PubMed ID: 35962936
[TBL] [Abstract][Full Text] [Related]
32. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease.
Pabon MM; Bachstetter AD; Hudson CE; Gemma C; Bickford PC
J Neuroinflammation; 2011 Jan; 8():9. PubMed ID: 21266082
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
Grünblatt E; Mandel S; Youdim MB
Ann N Y Acad Sci; 2000; 899():262-73. PubMed ID: 10863545
[TBL] [Abstract][Full Text] [Related]
34. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
35. Auraptene and Other Prenyloxyphenylpropanoids Suppress Microglial Activation and Dopaminergic Neuronal Cell Death in a Lipopolysaccharide-Induced Model of Parkinson's Disease.
Okuyama S; Semba T; Toyoda N; Epifano F; Genovese S; Fiorito S; Taddeo VA; Sawamoto A; Nakajima M; Furukawa Y
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763495
[TBL] [Abstract][Full Text] [Related]
36. α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease.
Kim BW; Koppula S; Kumar H; Park JY; Kim IW; More SV; Kim IS; Han SD; Kim SK; Yoon SH; Choi DK
Neuropharmacology; 2015 Oct; 97():46-57. PubMed ID: 25983275
[TBL] [Abstract][Full Text] [Related]
37. Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system.
Binukumar BK; Bal A; Gill KD
Neuromolecular Med; 2011 Dec; 13(4):251-65. PubMed ID: 21964614
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effects of metformin on traumatic brain injury in rats associated with NF-κB and MAPK signaling pathway.
Tao L; Li D; Liu H; Jiang F; Xu Y; Cao Y; Gao R; Chen G
Brain Res Bull; 2018 Jun; 140():154-161. PubMed ID: 29698747
[TBL] [Abstract][Full Text] [Related]
39. Inflammation in Parkinson's disease: causative or epiphenomenal?
Hald A; Van Beek J; Lotharius J
Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
[TBL] [Abstract][Full Text] [Related]
40. Microglial MT1 activation inhibits LPS-induced neuroinflammation via regulation of metabolic reprogramming.
Gu C; Wang F; Zhang YT; Wei SZ; Liu JY; Sun HY; Wang GH; Liu CF
Aging Cell; 2021 Jun; 20(6):e13375. PubMed ID: 33964119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
